A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation

Blood

Volumn 99, Issue 5, 2002, Pages 1840-1849

  Kean, Leslie S ^a   Durham, Megan M ^a   Adams, Andrew B ^a   Hsu, Lewis L ^a   Perry, Jennifer R ^a   Dillehay, Dirck ^a   Pearson, Thomas C ^a   Waller, Edmund K ^a   Larsen, Christian P ^a   Archer, David R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; MYELOABLATIVE AGENT;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT REJECTION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HLA MATCHING; LEUKOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; TREATMENT OUTCOME;

EID: 0036493491     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1840     Document Type: Article

References (44)

1. Barriers to bone marrow transplantation for sickle cell anemia
2. Bone marrow transplantation in sickle cell anemia-the dilemma of choice
3. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report
4. Haematopoietic stem cell transplantation for sickle cell anemia
5. Nonmyeloablative stem cell transplants
6. Bone marrow transplantation without myeloablation for sickle cell disease
7. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia
8. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy
9. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
10. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen
11. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
12. Extrathymic T-cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T-cell tolerance
13. Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning
14. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression
15. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation
16. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease
17. Knockout-transgenic mouse model of sickle cell disease
18. Identification of CD71 (transferrin receptor) expressing erythrocytes by multiparameter-flow-cytometry (MP-FCM): Correlation to the quantitation of reticulocytes as determined by conventional microscopy and MP-FCM using a RNA-staining dye
19. Methodologic considerations for the use of canine in vivo aged biotinylated erythrocytes to study RBC senescence
20. Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase C delta
21. Transmembrane phospholipid distribution in blood cells: Control mechanisms and pathophysiological significance
22. Genes encoding deletion of Vβ11 T-cells cosegregate with mammary tumour virus genomes
23. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V β 11-bearing T-cells
24. Determination of lymphocyte division by flow cytometry
25. Reticulocytosis and apoptosis: Ineffective erythropoiesis occurs in b-thalassemic but not in sickle mice
26. α 4 β 1-integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-1dependent binding to endothelium
27. Integrin α 4 β 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia
28. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow cytometric measurement and clinical association
29. Detection of altered membrane phospholipid assymetry in subpopulation of human red blood cells using fluorescently labeled annexin V
30. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium
31. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V
32. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated non-specific flip-flop and is enhanced by loss of the aminophospholipid translocase
33. Bone marrow transplantation for hemoglobidopathies
34. Bone marrow transplantation in sickle cell anemia
35. The panoply of animal models for sickle cell anemia
36. Sickle cell anemia as an inflammatory disease
37. Activated monocytes in sickle cell disease: Potential role in the activation of vascular endothelium and vaso-occlusion
38. Prediction of adverse outcomes in children with sickle cell disease
39. The acute chest syndrome in sickle cell disease: Incidence and risk factors
40. Cerebrovascular accidents in sickle cell disease: Rates and risk factors
41. Silent cerebral infarcts in sickle cell anemia: A risk factor analysis. The Cooperative Study of Sickle Cell Disease
42. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
43. Lymphoid development from hematopoietic stem cells
44. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages